Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have been given an average rating of “Moderate Buy” by the twenty-one analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $60.68.
Several brokerages have recently commented on IONS. Leerink Partnrs raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 24th. Wells Fargo & Company lowered their target price on Ionis Pharmaceuticals from $85.00 to $82.00 and set an “overweight” rating on the stock in a report on Wednesday, May 8th. Jefferies Financial Group assumed coverage on Ionis Pharmaceuticals in a research report on Tuesday, July 16th. They issued a “buy” rating and a $75.00 price target for the company. Bank of America increased their price objective on shares of Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Stifel Nicolaus lifted their target price on shares of Ionis Pharmaceuticals from $50.00 to $53.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th.
Get Our Latest Analysis on IONS
Insider Activity at Ionis Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Algert Global LLC raised its stake in shares of Ionis Pharmaceuticals by 149.2% in the 2nd quarter. Algert Global LLC now owns 75,350 shares of the company’s stock valued at $3,591,000 after acquiring an additional 45,108 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Ionis Pharmaceuticals by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 274,850 shares of the company’s stock valued at $13,099,000 after purchasing an additional 29,783 shares in the last quarter. Great Point Partners LLC purchased a new position in Ionis Pharmaceuticals in the second quarter valued at about $15,728,000. Marshall Wace LLP lifted its stake in shares of Ionis Pharmaceuticals by 1,021.5% during the second quarter. Marshall Wace LLP now owns 173,199 shares of the company’s stock worth $8,255,000 after purchasing an additional 157,756 shares in the last quarter. Finally, Logos Global Management LP purchased a new stake in shares of Ionis Pharmaceuticals in the second quarter worth about $14,298,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.
Ionis Pharmaceuticals Price Performance
Ionis Pharmaceuticals stock opened at $46.46 on Friday. The company has a debt-to-equity ratio of 4.15, a quick ratio of 7.28 and a current ratio of 7.37. Ionis Pharmaceuticals has a one year low of $35.95 and a one year high of $54.44. The company has a market cap of $6.78 billion, a P/E ratio of -17.40 and a beta of 0.40. The business has a fifty day moving average of $46.46 and a two-hundred day moving average of $44.13.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative net margin of 44.90% and a negative return on equity of 109.65%. The firm had revenue of $225.00 million during the quarter, compared to analysts’ expectations of $152.35 million. During the same quarter last year, the business earned $0.60 earnings per share. The business’s revenue for the quarter was up 19.7% compared to the same quarter last year. As a group, analysts predict that Ionis Pharmaceuticals will post -3.9 earnings per share for the current fiscal year.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
See Also
- Five stocks we like better than Ionis Pharmaceuticals
- What is the Hang Seng index?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 8/12 – 8/16
- Technology Stocks Explained: Here’s What to Know About Tech
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.